Carcinogenicity of antihypertensive therapy

Pharmacology, Toxicology and Pharmaceutical Science

• Antihypertensive Agent 100%
• Malignant Neoplasm 100%
• Prospective Study 100%
• Antihypertensive Therapy 100%
• Dipeptidyl Carboxypeptidase Inhibitor 100%
• Retrospective Study 100%
• Breast Cancer 100%
• Carcinogenicity 100%
• Diuretics 100%
• Reserpine 100%
• Cohort Study 50%
• Clinical Trial 50%
• Calcium Antagonist 50%
• Colon Carcinoma 50%
• Atenolol 50%
• Diuretic Therapy 50%
• Hypertension 50%

Keyphrases

• Antihypertensive Therapy 100%
• Carcinogenicity 100%
• Case-controlled Study 100%
• Malignancy 75%
• Breast Cancer 50%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 50%
• Diuretics 50%
• Reserpine 50%
• Meta-analysis 25%
• Non-associated 25%
• Increased Mortality 25%
• Hypertension Management 25%
• Prospective Clinical Trial 25%
• Calcium Antagonists 25%
• Clinical Practice Guidelines 25%
• Current Treatment 25%
• Data Combination 25%
• Cancer Risk 25%
• Risk of Malignancy 25%
• Protective Effect 25%
• Colon Cancer 25%
• Randomized Controlled Study 25%
• Weak Association 25%
• Atenolol 25%
• Renal Cancer 25%
• Diuretic Therapy 25%
• Antihypertensive Drug Class 25%
• Clinical Concerns 25%